In conditions of cardiac hypertrophy induced by angiotensin II (Ang II), it was demonstrated that breviscapine may still have a protective potential against cardiac hypertrophy by disrupting PKC-alpha-dependent ERK1/2 and PI3K/AKT signaling both in cardiac myocytes in vitro and mice in vivo (Yan et al., 2010). The gene discussed is AGT; the disease is cardiac hypertrophy.